» Articles » PMID: 10493497

The Tobacco-specific Carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a Beta-adrenergic Agonist and Stimulates DNA Synthesis in Lung Adenocarcinoma Via Beta-adrenergic Receptor-mediated Release of Arachidonic Acid

Overview
Journal Cancer Res
Specialty Oncology
Date 1999 Sep 24
PMID 10493497
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

Lung cancer is the leading cause of death in the United States, and it demonstrates a strong etiological association with smoking. The nicotine-derived nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) reproducibly induces pulmonary adenocarcinomas (ACs) in laboratory rodents and is considered an important contributing factor to the high lung cancer burden observed in smokers. It has been shown that the development of NNK-induced ACs in mice is reduced by inhibitors of cyclooxygenase and lipoxygenase and that the growth of human AC cell lines is regulated by beta-adrenergic receptors. On the basis of structural similarities of NNK with classic beta-adrenergic agonists, we tested the hypothesis that NNK stimulates the growth of human AC cells via agonist-binding to beta-adrenergic receptors, resulting in the release of arachidonic acid (AA). In support of this hypothesis, radioreceptor assays with transfected CHO cell lines stably expressing the human beta1- or beta2-adrenergic receptor demonstrated high affinity binding of NNK to each of these receptors. Two human AC cell lines expressed beta1- and beta2-adrenergic receptors by reverse transcription-PCR and responded to NNK with the release of AA and an increase in DNA synthesis. Beta-adrenergic antagonists completely blocked the release of AA and increase in DNA synthesis. The cyclooxygenase inhibitor aspirin and the 5-lipoxygenase inhibitor MK-886 both partially inhibited DNA synthesis in response to NNK. Our findings identify the direct interaction of NNK with beta-adrenergic, AA-dependent pathways as a novel mechanism of action which may significantly contribute to the high cancer-causing potential of this nitrosamine. Moreover, NNK may also contribute to the development of smoking-related nonneoplastic disease via this mechanism.

Citing Articles

Lung cancer associated with combustion particles and fine particulate matter (PM) - The roles of polycyclic aromatic hydrocarbons (PAHs) and the aryl hydrocarbon receptor (AhR).

Holme J, Vondracek J, Machala M, Lagadic-Gossmann D, Vogel C, Le Ferrec E Biochem Pharmacol. 2023; 216:115801.

PMID: 37696458 PMC: 10543654. DOI: 10.1016/j.bcp.2023.115801.


Opportunities and Challenges of Kava in Lung Cancer Prevention.

Freeman B, Mamallapalli J, Bian T, Ballas K, Lynch A, Scala A Int J Mol Sci. 2023; 24(11).

PMID: 37298489 PMC: 10253622. DOI: 10.3390/ijms24119539.


The tobacco-specific carcinogen NNK induces pulmonary tumorigenesis via nAChR/Src/STAT3-mediated activation of the renin-angiotensin system and IGF-1R signaling.

Boo H, Min H, Hwang S, Lee H, Lee J, Oh S Exp Mol Med. 2023; 55(6):1131-1144.

PMID: 37258578 PMC: 10317988. DOI: 10.1038/s12276-023-00994-2.


Indoor Secondary Pollutants Cannot Be Ignored: Third-Hand Smoke.

Wu J, Lau A, Xu Y Toxics. 2022; 10(7).

PMID: 35878269 PMC: 9316611. DOI: 10.3390/toxics10070363.


LKB1 phosphorylation and deactivation in lung cancer by NNAL, a metabolite of tobacco-specific carcinogen, in an isomer-dependent manner.

Bian T, Wang Y, Botello J, Hu Q, Jiang Y, Zingone A Oncogene. 2022; 41(33):4042-4054.

PMID: 35835853 DOI: 10.1038/s41388-022-02410-x.